Investors Relations

Welcome to the Oblique Therapeutics Investor Relations page
On this section you can find documents, and other information regarding Oblique Therapeutics.

 

Oblique Therapeutics AB is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and aggressive metastatic cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome

 

Please do not hesitate to contact us to learn more about our research and technology or to discuss potential collaborations and partnerships. We look forward to hearing from you.

Contact us directly

Owe Orwar

CEO

+46(0)705-202 217

owe@obliquet.com

Daniel Johnsson

Chairman of the Board